From trials to a real hospital setting: Effectiveness of pegylated interferon-α-2b/ribavirin combination therapy for naïve chronic hepatitis C patients

Digestive Diseases and Sciences

Volumn 51, Issue 9, 2006, Pages 1619-1626

  Piai, Guido ^a   Scalice, Elisa ^a   Focareta, Rosaria ^a   Terracciano, Fulvia ^a   De Filippo, Francesca Romana ^a   Forte, Giovambattista ^a  

^a AORN San Sebastiano   (Italy)

Author keywords

Chronic hepatitis C; Hospital outpatient clinic; Pegylated interferon 2b; Recombinant interferon 2b; Treatment effectiveness

Indexed keywords

ALPHA2B INTERFERON; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; ASTHENIA; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRY SKIN; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEADACHE; HEPATITIS C; HUMAN; INJECTION SITE REACTION; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MENTAL DISEASE; MYALGIA; NAUSEA; OUTPATIENT CARE; PRIORITY JOURNAL; PRURITUS; SIDE EFFECT; WEIGHT REDUCTION;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; ODDS RATIO; RETROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VIRAL LOAD;

EID: 33748601240     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-006-9110-8     Document Type: Article

References (21)

1. McHutchison JG, Davis GL, Esteban R, Poynard T, Ling M-H, Garaud J-J, Albrecht J (2001) Durability of sustained virological response in patients with chronic hepatitis C after treatment with interferon alfa 2b alone or in combination with ribavirin. Hepatology 34:244A
2. Imazeki F, Yokosuka O, Fukai K, Saisho H (2003) Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study. Hepatology 38:493-502
3. Khokhar N (2004) Late relapse in chronic hepatitis C after sustained viral response to interferon and ribavirin. Journal of Gastroenterology and Hepatology 19:471-472
4. EASL International Consensus Conference on Hepatitis C (1999) Consensus statement. J Hepatol 30:956-961
5. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, Zarski JP (1996) Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 24:778-789
6. McHutchison JG, Poynard T (1999) Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C. Semin Liver Dis 19 Suppl 1:57-65
7. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, Shiffman ML, Zeuzem S, Craxi A, Ling MH, Albrecht J (1998) Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 339:1493-1499
8. Piai G, Rocco P, Tartaglione MT, Ciarleglio A, Focareta R, Grimaldi E, Ievoli F, Iuliano D, Pacelli M, Forte G (2003) Triple (interferon, ribavirin, amantadine) versus double (interferon, ribavirin) re-therapy for interferon relapser genotype 1b HCV chronic active hepatitis patients. Hepatol Res 25:355-363
9. Saracco G, Olivero A, Ciancio A, Carenzi S, Smedile A, Cariti G, Andreoni M, Orsi PG, Biglino A, Tabone M, Roffi L, Croce G, Manca A, Tappero G, Ciccone G, Rizzetto M (2001) A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C not responding to interferon alone. Hepatology 34:133-138
10. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, O'Grady J, Reichen J, Diago M, Lin A, Hoffman J, Brunda MJ (2000) Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 343:1666-1672
11. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347:975-982
12. Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, Schiff ER, Goodman ZD, Laughlin M, Yao R, Albrecht JK (2001) Hepatitis Interventional Therapy Group. A randomized, double blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 34:395-403
13. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 358:958-965
14. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J (1981) Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1:431-435
15. McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, Dienstag J, Lee WM, Mak C, Garaud JJ, Albrecht JK (2002) International Hepatitis Interventional Therapy Group. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 123:1061-1069
16. Hadziyannis SJ, Sette HJr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer HJr, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM (2004) PEGASYS International Study Group. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140:346-355
17. Shehab TM, Fontana RJ, Oberhelman K, Marrero JA, Su GL, Lok AS (2004) Effectiveness of interferon alpha-2b and ribavirin combination therapy in the treatment of naive chronic hepatitis C patients in clinical practice. Clin Gastroenterol Hepatol 2:425-431
18. Jensen DM, Cotler SJ, Lam H, Harb G, Shillington A (2004) A comparison of hepatitis C treatment and outcomes at academic, private and Veterans' Affairs treatment centers. Aliment Pharmacol Ther 19:69-77
19. Kumar D, Wallington-Beddoe C, George J, Lin R, Samarasinghe D, Liddle C, Farrell GC (2003) Effectiveness of interferon alfa-2b/ribavirin combination therapy for chronic hepatitis C in a clinic setting. Med J Aust 178:267-271
20. Clouston AD, Jonsson JR, Purdie DM, Macdonald GA, Pandeya N, Shorthouse C, Powell EE (2001) Steatosis and chronic hepatitis C: analysis of fibrosis and stellate cell activation. J Hepatol 34:314-320
21. Falck-Ytter Y, Kale H, Mullen KD, Sarbah SA, Sorescu L, McCullough AJ (2002) Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 136:288-292